Research Grade Vamikibart (HY328176)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.

HY328176

Description

Vamikibart (HY328176) is a research-grade recombinant antibody targeting Hybridoma growth factor. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Species reactivity

Human

Applications

ELISA, Bioactivity: FACS, Functional assay, Research in vivo, WB

Host species

Human

Isotype

IgG2-kappa

Expression system

Mammalian Cells

Clonality

Monoclonal

Tested applications

Target

Hybridoma growth factor, BSF-2, IFN-beta-2, CDF, IL6, Interleukin-6, IL-6, B-cell stimulatory factor 2, Interferon beta-2, IFNB2, CTL differentiation factor

Endotoxin level

Please contact the lab for this information.

Purity

>95% purity as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P05231

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

Alternate Names

2744320-12-3

Background

Interleukin-6 (IL6) is a ~23 kDa protein. Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable). IL6 is the therapeutic target of tocilizumab (Actemra).

Note

For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for Research Grade Vamikibart.
Bioactivity

Detects recombinant IL6 (Catalog No: HY328021) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-IL6 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human IL6 (Catalog No: HY328021)
Lane 2: Negative control